Here's Why Momentum in Catalyst (CPRX) Should Keep going
Catalyst (CPRX) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Catalyst (CPRX) Soars 16.7%: Is Further Upside Left in the Stock?
Catalyst (CPRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Why Catalyst Pharmaceutical (CPRX) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Is Catalyst (CPRX) Down 6.7% Since Last Earnings Report?
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock?
Why Catalyst Pharmaceutical (CPRX) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
CPRX Q3 Earnings & Revenues Beat Estimates, '24 View Raised, Stock Up
Catalyst stock gains on strong third-quarter results, beating earnings and revenue estimates, primarily driven by Firdapse sales. Management raises sales guidance.
Catalyst Pharmaceuticals, Inc. (CPRX) Q3 2024 Earnings Call Transcript
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX ) Q3 2024 Earnings Conference Call November 7, 2024 8:30 AM ET Company Participants Richard Daly - President and Chief Executive Officer Michael Kalb - Chief Financial Officer Jeffrey Del Carmen - Chief Commercial Officer Steven Miller - Chief Operating Officer and Chief Scientific Officer Gary Ingenito - Chief Medical & Regulatory Officer Conference Call Participants Joon Lee - Truist Securities Charles Duncan - Cantor Fitzgerald Samantha Semenkow - Citi Investment Research Operator Thank you for standing by. My name is Kris and I will be your conference operator today.
Catalyst Pharmaceuticals, Inc. (CPRX) Hit a 52 Week High, Can the Run Continue?
Catalyst (CPRX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Catalyst (CPRX) Reports Q3 Earnings: What Key Metrics Have to Say
The headline numbers for Catalyst (CPRX) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
